Asenapine Maleate

FDA Drug Profile — SAPHRIS

Asenapine Maleate is listed in the FDA National Drug Code directory with 17 NDC codes, marketed under brand name including SAPHRIS. Available dosage forms: tablet, powder.

Drug Details

Generic Name
Asenapine Maleate
Brand Names
SAPHRIS
Application Number
NDA022117
Sponsor
Allergan, Inc.
NDC Codes
17
Dosage Forms
TABLET, POWDER
Routes
SUBLINGUAL
Active Ingredients
ASENAPINE MALEATE

Indications and Usage

1 INDICATIONS AN D USAGE SAPHRIS is indicated for: Schizophrenia in adults [see Clinical Studies ( 14.1 )] Bipolar I disorder [see Clinical Studies ( 14.2 )] • Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age • Adjunctive treatment to lithium or valproate in adults • Maintenance monotherapy treatment in adults SAPHRIS is an atypical antipsychotic indicated for ( 1 ): Schizophrenia in adults Bipolar I disorder ○ Acute monotherapy treatment of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age ○ Adjunctive treatment to lithium or valproate in adults ○ Maintenance monotherapy treatment in adults